HealthStream (HSTM) Stock Price Climbs As Rich Valuation Draws Focus

HealthStream stock jumped about 5% today to US$29.80, extending a strong three month run, as investors reacted to what the company called record second quarter results. Revenue reached US$83.7m and basic earnings per share came in at roughly US$0.23, both important markers for a healthcare software vendor that lives on recurring contracts and bundled platforms.

The short term story is the pop in the share price. The longer term question for you is whether a business growing high single digits with a P/E near 41x and a 6.6% net margin still offers enough runway to justify that kind of multiple.

Love the recurring revenue story at HealthStream but unsure about paying a P/E near 41x for mid single digit growth and a 6.6% net margin? Consider exploring our list of solid balance sheet and fundamentals stocks (49 results) for companies that pair steady fundamentals with more modest valuation profiles.

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs. Q2 2025: US$83.7m vs. US$74.4m (up about 12.5%)
• Net Income, Q2 2026 vs. Q2 2025: US$6.7m vs. US$5.4m (year-on-year increase)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.23 vs. US$0.18 (higher earnings per share)
• Trailing Net Margin, last 12 months vs. prior year: 6.6% vs. 6.9% (slight margin compression alongside higher earnings)

Prefer clear charts instead of another dense block of earnings tables and ratios? See HealthStream's valuation, growth and profitability laid out in one visual, easy to scan view in the company report for HealthStream.

HealthStream bull case leans on real platform traction

Bulls argue HealthStream is turning into a true healthcare workforce platform with healthier recurring growth and better earnings conversion. Q2 gives that view some backing. Total revenue grew 12.5% with organic growth of about 8.3%. Subscription revenue grew 11.2% even before acquisitions, which fits the story of stickier, contract based demand. Key modern products are pulling their weight. CredentialStream grew 14%, ShiftWizard 30%, Competency Suite 12%, while myClinicalExchange rose 29% and is getting extra sales hires. Insights users moved from roughly 100 to more than 2,600 in a year, which supports the data platform angle management talks about. Adjusted EBITDA of US$20.6m grew faster than revenue at 16.9% and operating income grew 41.4%. That points to real operating leverage despite higher investment.

Bear case focuses on quality of growth and legacy drag

Bears worry that HealthStream relies on one offs, faces legacy drag and rising competition, which could cap long term growth and margins. Q2 does not fully clear those concerns. Growth benefited from US$3.1m of acquired revenue and a US$2.0m one time catch up from an older ANSOS contract that is not recurring. Management also folded that catch up into full year guidance, which makes true underlying growth harder to read. Legacy credentialing and scheduling revenue fell 15% to US$7.4m. The migration story is working but also shows continued drag until transitions complete. Net income guidance was trimmed even as revenue and adjusted EBITDA guidance were raised. That points to the cost of higher product, sales and event spending. The disclosed cybersecurity incident, while labeled non material, keeps regulatory and data privacy risk on the radar.

Compare HealthStream's internal momentum on subscriptions, product uptake and margins with what institutional analysts are signaling on the stock. See the consensus price target analysis for HealthStream to check how the street's targets compare with the latest 5% move.

Stay Ahead With HealthStream Insights

If HealthStream's record Q2 results and recent 5% share price move have your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the P/E and margins evolve over time. Once you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on essential updates that matter to your holdings. For a broader view, tap into crowd wisdom through the Community and see how other investors are thinking about HealthStream and similar stocks. By spotting hidden catalysts and potential risks early, you may improve your ability to stay ahead of the market.

Seeking Alternatives Beyond HealthStream Today

Fresh stock stories can move from quiet buildup to breakout momentum quickly. Spot ideas flying under the radar for now and refresh your watchlist before the crowd moves. Act now.

• Scan for resilient compounders with room to run by checking companies in the 85 resilient stocks with low risk scores while they are still under the radar for many investors.
• Position ahead of potential AI tailwinds by reviewing the curated set of 68 profitable AI stocks that aren't just burning cash before enthusiasm pushes valuations away from your preferred entry points.
• Target growing cash flows supported by hard assets through the focused group of 8 top copper producer stocks while these opportunities remain priced for early movers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com